Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Earlier this month, Health Canada added certain psychedelic compounds to the SAP that were previously available only through clinical trials. investment community.”

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain.

Data 105

Data Clinical Trials Research and Development Indica 105

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Neurological Disorders: Several cannabinoids show promise in the treatment of neurological disorders, including multiple sclerosis (MS) and Parkinson’s disease.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Patients can also access CBD products without a prescription through local pharmacies. Parkinson’s disease and cannabis.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JANUARY 12, 2022

Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. This would answer questions about safety and efficacy, they said. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Mitchell et al., Divito & Robert F. Psychiatry May Never Be the Same , N.Y.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. The company initiated the first legal transfer (as deemed by federal law) to the U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Since then, “ketamine clinics” have proliferated throughout the U.S., Id ; 21 CFR 312.1-10;

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

JULY 14, 2021

(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence. federal law.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. for the production of cannabis used in federally-regulated clinical trials.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Law Report

DECEMBER 2, 2021

Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours). Psilocybin Pharmacology, Neuroscience, and Clinical Research (12 Hours). Programs shall train students on how to proactively make psilocybin services accessible to people with disabilities. Core Psilocybin Facilitation Skills (16 Hours).

Law 52

Law Programs Therapy Education 52

The Cannigma

JULY 1, 2022

Preclinical studies involve exposing cells and animals to treatments to see if there are indications that the treatment could be worth evaluating in humans. Clinical studies are performed in people and can be controlled in various ways to understand how people respond to a treatment.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Commence clinical program in PTSD. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Accelerate adoption across a broader prescriber base.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Le-Short C.,

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Steve Barbera is an accomplished cross-functional leader in the healthcare industry, with over 20 years of experience in the development and implementation of complex market access strategies including health policy, pricing and reimbursement, contracts and coding. Sesen Bio, Inc.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. CBG, however, also has some medicinal potential that CBD doesn’t, for instance as a treatment for hypertension and insulin resistance. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

The Cannigma

DECEMBER 12, 2022

Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Iboga safety: Numerous concerns about the safety of iboga have been raised by scientists.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Veriheal

AUGUST 31, 2020

Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi. Program between St.

Research and Development 117

Research and Development Education Agriculture Patients 117

Veriheal

JUNE 29, 2022

Psilocybin , a psychedelic compound found in a variety of mushrooms, has long been used as a tool to mitigate depression despite the limited amount of research on its efficacy and safety. Exploring Psilocybin and Treatment-Resistant Depression. Future Trials With COMP360 Psilocybin. Dr. David J.

Clinical Trials 104

Clinical Trials Blood Pressure Treatment Therapy 104

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Canna Law Blog

NOVEMBER 6, 2021

To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. But only if it is made affordable and accessible.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

JANUARY 13, 2023

8 A 2018 animal study using THC on rats concluded that “THC reduces migraine-like pain when administered at the right dose” and there is “anecdotal evidence for the use of cannabinoids as a treatment for migraine in humans and implicate the CB1 receptor as a therapeutic target for migraine.” headaches per month.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

JUNE 11, 2019

Despite the recent legalization of cannabis, a framework for access to cannabis for medical purposes still exists, but under new regulations passed under the authority of the Cannabis Act. Compensation is not payable for treatments that “simply improve the plaintiff’s enjoyment of life” 32.

Chronic Pain 45

Chronic Pain Cannabis History Treatment 45